Spectral AI, Inc. Warrants

Spectral AI showcased its DeepView System at the Southern Region Burn Conference, demonstrating its AI technology for objective burn wound assessment. The company aims to improve patient outcomes and reduce healthcare costs through innovative medical diagnostics.

Spectral AI reported a net loss of $3.6 million in Q3 2025, reduced revenue guidance to $18.5 million, and anticipates a flat to slightly lower revenue year in 2026. The company continues to progress towards FDA clearance for its DeepView medical device and is expanding international market presence.

The White House is encouraging AI adoption in healthcare through regulatory sandboxes, with several tech and biotech companies advancing AI-powered healthcare solutions focused on diagnostics, drug development, and workflow optimization.